Skip to main content

Table 2 Combination index values for ReoT3D-chemotherapeutic combination regimens in NSCLC cells

From: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

   

Combination Index Values§

 

Combination Index Values§

Drugs & Cell Lines

Drug Sensitivity ¶ IC50 (μM)

Ratio* I

ED50

ED75

ED90

Mean

Ratio* II

ED50

ED75

ED90

Mean

Paclitaxel

           

   NCI-H460

0.003 ± 0.001

1:53

0.903

0.221

0.057

0.394

1:533

0.193

0.042

0.013

0.083

   HOP-92

38.50 ± 16.01

1:20

0.144

0.295

0.613

0.351

1:200

0.178

0.420

0.994

0.530

   NCI-H23

0.08 ± 0.04

1:20

0.577

0.303

0.159

0.347

1:200

0.329

0.061

0.011

0.134

   EKVX

56.06 ± 15.87

1:20

0.294

0.440

0.660

0.464

1:200

0.124

0.216

0.374

0.238

   NCI-H226

77.79 ± 25.08

1:20

0.543

0.344

0.218

0.368

1:200

0.004

1.30E-04

4.73E-06

0.001

   NCI-H322M

> 100

1:20

0.069

0.092

0.133

0.098

1:200

0.078

0.081

0.084

0.081

Cisplatin

           

   NCI-H460

5.31 ± 1.21

1:53

0.875

0.313

0.112

0.433

1:533

0.661

0.292

0.129

0.361

   HOP-92

6.82 ± 3.22

1:20

0.352

0.325

0.500

0.392

1:200

0.053

0.080

0.195

0.109

   NCI-H23

3.51 ± 1.15

1:20

0.579

0.487

0.530

0.532

1:200

0.546

0.248

0.342

0.379

   EKVX

29.34 ± 6.62

1:20

0.955

0.559

0.328

0.614

1:200

0.933

0.754

0.610

0.766

   NCI-H226

14.71 ± 6.60

1:20

0.615

0.297

0.145

0.352

1:200

0.558

0.081

0.013

0.217

   NCI-H322M

> 100

1:20

> 10

> 10

> 10

> 10

1:200

> 10

> 10

> 10

> 10

Gemcitabine

           

   NCI-H460

0.01 ± 0.003

1:53

0.199

0.126

0.126

0.150

1:533

0.006

0.017

0.054

0.025

   HOP-92

0.83 ± 0.61

1:20

0.372

0.117

0.047

0.179

1:200

0.099

0.110

0.127

0.112

   NCI-H23

0.02 ± 0.01

1:20

0.630

0.249

0.285

0.388

1:200

0.207

0.092

0.369

0.223

   EKVX

> 100

1:20

> 10

> 10

> 10

> 10

1:200

> 10

> 10

> 10

> 10

   NCI-H226

17.69 ± 10.16

1:20

0.112

0.030

0.008

0.050

1:200

0.057

0.007

0.001

0.021

   NCI-H322M

> 100

1:20

> 10

> 10

> 10

> 10

1:200

> 10

> 10

> 10

> 10

Vinblastine

           

   NCI-H460

0.92 ± 0.35 (nM)

1:5.3

0.255

0.149

0.089

0.164

1:53.3

0.069

0.045

0.031

0.049

   HOP-92

48.80 ± 23.08

1:20

1.749

7.049

> 10

> 10

1:200

0.133

1.256

11.922

4.437

   NCI-H23

1.49 ± 1.09 (nM)

1:2

0.316

0.056

0.019

0.130

1:20

0.367

0.052

0.008

0.142

   EKVX

> 100

1:20

3.275

1.927

1.134

2.112

1:200

0.193

0.651

2.192

1.012

   NCI-H226

28.46 ± 14.13

1:20

0.081

0.043

0.023

0.049

1:200

0.027

0.006

0.001

0.012

   NCI-H322M

> 100

1:20

> 10

> 10

> 10

> 10

1:200

> 10

> 10

> 10

> 10

  1. ¶Sensitivities of 6 NSCLC cell lines to each listed drug tested as a single agent (mean ± SD from 3 separate experiments). *Constant ratios of drug concentrations in μM (or nM) and ReoT3D MOI doses in plaque forming units per cell used for combination studies (see text). §Combination index (CI) values shown are from representative experiments repeated three times with similar results. Abbreviations: ReoT3D, reovirus type 3 Dearing; NSCLC, non-small cell lung cancer; IC50, 50% inhibitory concentration; MOI, multiplicity of infection expressed in plaque forming units per cell.
Back to article page

Molecular Cancer

ISSN: 1476-4598